ReviewStem cells international2014
Management of fibrosis: the mesenchymal stromal cells breakthrough.
Review in Stem cells international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem cells translational medicine · 2022Pooled it
- Mesenchymal Stromal Cell Therapy for Pancreatitis: A Systematic Review.Oxidative medicine and cellular longevity · 2018Pooled it
- Hydrogels for Healing Radiation-Injured Tissues and Organs.Gels (Basel, Switzerland) · 2026Review
- Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026Review
- TGF-β-induced fibrotic scar formation limits recovery of spinal cord injury.Bone research · 2026Article
- High-intensity ethanol binge drinking pattern in adolescence induces long-lasting impairment in the salivary glands and saliva quality of rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Research progress on the role of mesenchymal stem cells in pyroptosis in sepsis.Stem cell research & therapy · 2025Review
- Evolution of cell therapies derived from adipose tissue: historical perspectives, current development trends and future directions.Biology direct · 2025Review
- Multi-function of adipose-derived stem cells on gut disorder: from bench to bedside.Stem cell research & therapy · 2025Review
- Cryoelectrospun elastin-alginate scaffolds as potential cell delivery vehicles for mesenchymal stromal cell therapy.Scientific reports · 2025Article
- Anti-aging based on stem cell therapy: A scoping review.World journal of experimental medicine · 2024Article
- Review
- Permissive role of vascular endothelium in fibrosis: focus on the kidney.American journal of physiology. Cell physiology · 2024Review
- Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Safety assessment of a three-dimensional-printed autologous omentum patch: An application on the kidneys as a new treatment approach.Clinical and translational science · 2023Article
- Advancements in adipose-derived stem cell therapy for skin fibrosis.World journal of stem cells · 2023Review
- Revolutionizing Radiotoxicity Management with Mesenchymal Stem Cells and Their Derivatives: A Focus on Radiation-Induced Cystitis.International journal of molecular sciences · 2023Review
- Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Based Modulation of Obstructive Sleep Apnea.International journal of molecular sciences · 2023Review
- Ultrasound Imaging of the Superficial Fascia in the Upper Limb: Arm and Forearm.Diagnostics (Basel, Switzerland) · 2022Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components. Despite its slow progression, it leads to organ malfunction. Fibrosis can affect almost any tissue. Due to its high frequency, in particular in the heart, lungs, liver, and kidneys, many studies have been conducted to find satisfactory treatments. Despite these efforts, current fibrosis management therapies either are insufficiently effective or induce severe adverse effects. In the light of these facts, innovative experimental therapies are being investigated. Among these, cell therapy is regarded as one of the best candidates. In particular, mesenchymal stromal cells (MSCs) have great potential in the treatment of inflammatory diseases. The value of their immunomodulatory effects and their ability to act on profibrotic factors such as oxidative stress, hypoxia, and the transforming growth factor-β1 pathway has already been highlighted in preclinical and clinical studies. Furthermore, their propensity to act depending on the microenvironment surrounding them enhances their curative properties. In this paper, we review a large range of studies addressing the use of MSCs in the treatment of fibrotic diseases. The results reported here suggest that MSCs have antifibrotic potential for several organs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.